These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
249 related articles for article (PubMed ID: 16110408)
21. Future directions in the treatment of androgen-independent prostate cancer. Petrylak DP Urology; 2005 Jun; 65(6 Suppl):8-12. PubMed ID: 15939077 [TBL] [Abstract][Full Text] [Related]
22. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Berthold DR; Pond GR; Roessner M; de Wit R; Eisenberger M; Tannock AI; Clin Cancer Res; 2008 May; 14(9):2763-7. PubMed ID: 18451243 [TBL] [Abstract][Full Text] [Related]
23. Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients. Vici P; Viola G; Botti C; Rossi S; Vitucci C; Corsetti S; Di Lauro L; Sergi D; Foggi P; Perri P; Tirelli C; Mottolese M; Fattoruso SI; Lopez M Clin Ter; 2008; 159(6):449-52. PubMed ID: 19169607 [TBL] [Abstract][Full Text] [Related]
24. New progress in treatment of hormone-refractory prostate cancer. Ahmad K Lancet Oncol; 2004 Dec; 5(12):706. PubMed ID: 15599999 [No Abstract] [Full Text] [Related]
25. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer]. Soria JC Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155 [No Abstract] [Full Text] [Related]
26. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress? Culine S; Droz JP Ann Oncol; 2000 Dec; 11(12):1523-30. PubMed ID: 11205458 [TBL] [Abstract][Full Text] [Related]
27. [Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer]. Ohlmann CH; Markert E; Gerharz M; Pfister D; Dienes HP; Engelmann U; Heidenreich A Urologe A; 2008 Sep; 47(9):1218-23. PubMed ID: 18679646 [TBL] [Abstract][Full Text] [Related]
28. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Collins R; Trowman R; Norman G; Light K; Birtle A; Fenwick E; Palmer S; Riemsma R Br J Cancer; 2006 Aug; 95(4):457-62. PubMed ID: 16880788 [TBL] [Abstract][Full Text] [Related]
29. Hormone refractory prostate cancer (HRPC): present and future approaches of therapy. Di Lorenzo G; De Placido S Int J Immunopathol Pharmacol; 2006; 19(1):11-34. PubMed ID: 16569343 [TBL] [Abstract][Full Text] [Related]
30. The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. Berry WR Urology; 2005 Jun; 65(6 Suppl):2-7. PubMed ID: 15939076 [TBL] [Abstract][Full Text] [Related]
31. Prostate cancer: The androgen receptor remains front and centre. Saylor PJ Nat Rev Clin Oncol; 2013 Mar; 10(3):126-8. PubMed ID: 23381000 [No Abstract] [Full Text] [Related]
32. [Therapeutic options for hormone-refractory prostate cancer]. Miller K; Börgermann C; Thüroff J; Albers P; Wirth M Urologe A; 2006 May; 45(5):580, 582-5. PubMed ID: 16710677 [TBL] [Abstract][Full Text] [Related]
33. [Promising new treatment options for metastatic androgen-independent prostate cancer]. Tan W Actas Urol Esp; 2007 Jun; 31(6):680-5. PubMed ID: 17896565 [TBL] [Abstract][Full Text] [Related]
34. Treatment options in hormone-refractory metastatic prostate carcinoma. Fusi A; Procopio G; Della Torre S; Ricotta R; Bianchini G; Salvioni R; Ferrari L; Martinetti A; Savelli G; Villa S; Bajetta E Tumori; 2004; 90(6):535-46. PubMed ID: 15762353 [TBL] [Abstract][Full Text] [Related]